Cover Page Document - shares	3 Months Ended
Cover Page Document - shares	Mar. 31, 2020	Apr. 23, 2020
Cover Page [Abstract]
Entity Central Index Key	0001371285
Entity Common Stock, Shares Outstanding		35,100,336
Entity Shell Company	false
Entity Filer Category	Large Accelerated Filer
Entity Interactive Data Current	Yes
Entity Current Reporting Status	Yes
Title of 12(b) Security	Common stock, $0.00001 par value per share
City Area Code	(855)
Entity Address, Address Line One	6100 4th Avenue S, Suite 200
Entity Address, City or Town	Seattle,
Entity Incorporation, State or Country Code	DE
Document Period End Date	Mar. 31, 2020
Document Transition Report	false
Document Quarterly Report	true
Entity File Number	001-36537
Entity Tax Identification Number	83-0480694
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	98108
Local Phone Number	727 - 9079
Trading Symbol	TRUP
Security Exchange Name	NASDAQ
Entity Small Business	false
Entity Emerging Growth Company	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Registrant Name	TRUPANION, INC.

Consolidated Statement of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
Revenue	$ 111,301	$ 86,978
Cost of Revenue [Abstract]
Veterinary invoice expense	79,640	61,282
Other Cost of Services Sold	13,809	10,664
Gross profit	17,852	15,032
Operating Expenses [Abstract]
Technology and Development Expense	2,845	2,669
General and Administrative Expense	5,516	5,419
Selling and Marketing Expense	10,442	8,227
Operating Expenses	18,803	16,315
Income (Loss) from Equity Method Investments	(59)	0
Operating loss	(1,010)	(1,283)
Interest expense	379	317
Other income, net	(282)	(344)
Income (Loss) before income taxes	(1,107)	(1,256)
Income tax expense	26	40
Net loss	$ (1,133)	$ (1,296)
Earnings Per Share, Basic and Diluted	$ (0.03)	$ (0.04)
Weighted Average Number of Shares Outstanding, Basic and Diluted	35,007,052	34,292,367

Consolidated Statement of Comprehensive Income Statement - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Statement of Comprehensive Income [Abstract]
Net loss	$ (1,133)	$ (1,296)
Foreign currency translation adjustments	(630)	189
Net unrealized (loss) gain on available-for-sale debt securities	(5)	19
Other comprehensive income (loss), net of taxes	(635)	208
Comprehensive Income (Loss)	$ (1,768)	$ (1,088)

Consolidated Balance Sheet - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Assets [Abstract]
Cash and cash equivalents	$ 27,221	$ 29,168
Short-term Investments	76,094	69,732
Accounts and other receivables	65,997	54,408
Prepaid expenses and other assets	5,766	5,513
Total current assets	175,078	158,821
Restricted Cash	1,400	1,400
Long-Term Investments, at fair value	4,094	4,323
Property and equipment, net	70,569	70,372
Intangible assets, net	7,571	7,731
Other Long-Term Assets	14,487	14,553
Total assets	273,199	257,200
Liabilities and Equity [Abstract]
Accounts payable	4,772	4,087
Accrued liabilities and other current liabilities	14,003	13,798
Reserve for veterinary invoices	22,862	21,194
Deferred Revenue	62,014	52,546
Total current liabilities	103,651	91,625
Long-term debt	29,844	26,086
Deferred Income Tax Liabilities, Net	1,118	1,118
Other liabilities	1,761	1,611
Total liabilities	136,374	120,440
Common stock	0	0
Preferred Stock	0	0
Additional paid-in capital	234,642	232,731
Accumulated other comprehensive loss	(385)	250
Accumulated deficit	(86,653)	(85,520)
Treasury stock, at cost	(10,779)	(10,701)
Stockholders' Equity Attributable to Parent	136,825	136,760
Total liabilities and stockholders' equity	$ 273,199	$ 257,200

Consolidated Balance Sheet Condensed Consolidated Balance Sheet Parentheticals - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Common Stock, Par or Stated Value Per Share	$ 0.00001	$ 0.00001
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	36,017,670	35,876,882
Common Stock, Shares, Outstanding	35,084,505	34,947,017
Preferred Stock, Par or Stated Value Per Share	$ 0.00001	$ 0.00001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Treasury Stock, Shares	933,165	929,865

Consolidated Statement of Stockholders' Equity Statement - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock [Member]
Common Stock, Shares, Outstanding Period Start at Dec. 31, 2018		34,025,136
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Redemption of warrants		276,120
Stock Issued During Period, Shares, Share-based Compensation, Net of Tax Withholdings		166,209
Common Stock, Shares, Outstanding Period End at Mar. 31, 2019		34,467,465
Stockholders' Equity Attributable to Parent Period Beginning at Dec. 31, 2018	$ 129,173	$ 0	$ 219,838	$ (83,711)	$ (753)	$ (6,201)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Settlement of warrant liabilities	0		4,500			(4,500)
Stock Issued During Period, Value, Share-based Compensation, Net of Tax Withholdings	507		507
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition	1,417		1,417
Other Comprehensive Income (Loss), Net of Tax	208				208
Net Income (Loss) Available to Common Stockholders, Basic	(1,296)			(1,296)
Stockholders' Equity Attributable to Parent Period End at Mar. 31, 2019	$ 130,009	$ 0	226,262	(85,007)	(545)	(10,701)
Common Stock, Shares, Outstanding Period Start at Dec. 31, 2019	34,947,017	34,947,017
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock Issued During Period, Shares, Share-based Compensation, Net of Tax Withholdings		140,788
Common Stock, Shares, Outstanding Period End at Mar. 31, 2020	35,084,505	35,084,505
Stockholders' Equity Attributable to Parent Period Beginning at Dec. 31, 2019	$ 136,760	$ 0	232,731	(85,520)	250	(10,701)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock Issued During Period, Value, Share-based Compensation, Net of Tax Withholdings	205		205
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition	$ 1,706		1,706
Stock Repurchased During Period, Shares	(3,300)
Treasury Stock, Value, Acquired, Cost Method	$ 78
Other Comprehensive Income (Loss), Net of Tax	(635)				(635)
Net Income (Loss) Available to Common Stockholders, Basic	(1,133)			(1,133)
Stockholders' Equity Attributable to Parent Period End at Mar. 31, 2020	$ 136,825	$ 0	$ 234,642	$ (86,653)	$ (385)	$ (10,779)

Consolidated Statement of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Statement of Cash Flows [Abstract]
Net Income (Loss) Available to Common Stockholders, Basic	$ (1,133)	$ (1,296)
Net Loss	(1,133)	(1,296)
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Depreciation and Amortization	1,381	1,613
Stock-based compensation expense	1,653	1,357
Other, Net	73	(3)
Increase (Decrease) in Operating Assets [Abstract]
Accounts and other receivables	(11,697)	(5,894)
Prepaid expenses and other assets	(195)	325
Accounts Payable, Accrued Liabilities, and Other Liabilities	1,322	1,256
Claims Reserve	1,825	1,078
Deferred revenue	9,695	5,523
Net cash provided by operating activities	2,924	3,959
Net Cash Provided by Investing Activities [Abstract]
Payments to Acquire Investments	(11,579)	(17,350)
Maturities of Investment Securities	5,100	10,205
Purchases of property and equipment	(1,496)	(878)
Payments for (Proceeds from) Other Investing Activities	9	(1,479)
Net cash used in investing activities	(7,966)	(9,502)
Net Cash Provided by Financing Activities [Abstract]
Proceeds from exercise of stock options	559	661
Payments Related to Tax Withholding for Share-based Compensation	(321)	(197)
Proceeds from Debt, Net of Issuance Costs	3,744	5,200
Proceeds from (Payments for) Other Financing Activities	(78)	(271)
Net cash provided by financing activities	3,904	5,393
Effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash, net	(809)	220
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	(1,947)	70
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	28,621	28,022
Supplemental Cash Flow Information [Abstract]
Redemption of Warrants Non-Cash; Common Stock	0	4,500
Purchases of property and equipment included in accounts payable and accrued liabilities	$ 355	$ 141

Nature of Operations and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations and Summary of Significant Accounting Policies	Nature of Operations and Significant Accounting Policies Description of Business and Basis of Presentation Trupanion, Inc. (collectively with its wholly-owned subsidiaries, the Company) provides medical insurance for cats and dogs throughout the United States, Canada and Puerto Rico. The financial data as of December 31, 2019 was derived from the Company's audited consolidated financial statements. The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and, in management's opinion, have been prepared on the same basis as the audited financial statements and include all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company's financial position, results of operations, comprehensive income (loss), stockholders' equity and cash flows for the interim periods. These unaudited interim consolidated financial statements should be read in conjunction with the Company’s audited financial statements included in the Company’s Annual Report on Form 10-K, filed with the U.S. Securities and Exchange Commission (SEC) on February 13, 2020 (the 2019 10-K). The Company's accounting policies are described in Note 1 to the audited financial statements included in the 2019 10-K. Operating results for the three months ended March 31, 2020 are not necessarily indicative of the results that may be expected for the full fiscal year or any other interim period. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates. See Note 1 to the audited financial statements included in the 2019 10-K for additional discussion of these estimates and assumptions. Recently Adopted Accounting Pronouncements The Company adopted Accounting Standards Update (ASU) 2016-13, Financial Instruments—Credit Losses (Topic 326), using the modified retrospective approach on January 1, 2020. The ASU replaces the incurred loss impairment methodology with a methodology that reflects expected credit losses and requires the use of a forward-looking expected credit loss model for accounts receivables, loans, and other financial instruments. The new standard did not have a material impact on the Company's consolidated statements of operations, balance sheets, stockholders' equity, or cash flows. The Company did not record any cumulative-effect adjustment to its retained earnings upon the adoption.

Net Loss per Share

3 Months Ended

Mar. 31, 2020

Earnings Per Share, Basic and Diluted [Abstract]

Earnings Per Share [Text Block]

Net Income (Loss) per Share

Basic net income (loss) per share is computed using the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per share is calculated using the weighted average number of shares of common stock plus, when dilutive, potential shares of common stock outstanding using the treasury-stock method. Potential shares of common stock outstanding include stock options, unvested restricted stock awards and restricted stock units, and warrants.

The following potentially dilutive equity securities were not included in the diluted earnings per share of common stock calculation because they would have had an antidilutive effect:



	Three Months Ended March 31,
	2020	2019
Stock options	2,046,395	2,513,946
Restricted stock awards and restricted stock units	506,863	716,319
Warrants	—	30,000

Investment Securities (Notes)

3 Months Ended

Mar. 31, 2020

Investments [Abstract]

Cost and Equity Method Investments Disclosure [Text Block]

Long-term investments are classified as available-for-sale and reported at fair value with unrealized gains and losses included in accumulated other comprehensive income (loss). Short-term investments are classified as held-to-maturity and reported at amortized cost. The amortized cost, gross unrealized holding gains and losses, and estimates of fair value of long-term and short-term investments by major security type and class of security were as follows as of March 31, 2020 and December 31, 2019 (in thousands):



	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Fair Value
As of March 31, 2020
Long-term investments:
Foreign deposits	$	3,099	$	—	$	—		$	3,099
Municipal bond	1,000		—		(5		)	995
	$	4,099	$	—	$	(5	)	$	4,094
Short-term investments:
U.S. Treasury securities	$	6,159	$	11	$	—		$	6,170
Certificates of deposit	1,565		—		—			1,565
U.S. government funds	68,370		—		—			68,370
	$	76,094	$	11	$	—		$	76,105

	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Fair Value
As of December 31, 2019
Long-term investments:
Foreign deposits	$	3,323	$	—	$	—		$	3,323
Municipal bond	1,000		—		—			1,000
	$	4,323	$	—	$	—		$	4,323
Short-term investments:
U.S. Treasury securities	$	6,156	$	—	$	(1	)	$	6,155
Certificates of deposit	440		—		—			440
U.S. government funds	63,136		—		—			63,136
	$	69,732	$	—	$	(1	)	$	69,731

Maturities of debt securities classified as available-for-sale were as follows (in thousands):



	As of March 31, 2020
	Amortized Cost		Fair Value
Available-for-sale:
Due after one year through five years	$	4,099	$	4,094
	$	4,099	$	4,094

The Company does not expect any credit losses from its held-to-maturity investments, considering the composition of the investment portfolio and the credit loss history of these investments. For available-for-sale debt securities, the Company determined that the unrealized losses were immaterial and due to non-credit factors. The Company does not intend to sell, nor is it more likely than not that the Company will be required to sell, the securities prior to maturity or prior to the recovery of the amortized cost basis.

Other Investments (Notes)	3 Months Ended
Other Investments (Notes)	Mar. 31, 2020
Investments, All Other Investments [Abstract]
Investments and Other Noncurrent Assets [Text Block]	Other Investments Investment in Variable Interest Entity In July 2018, the Company purchased $3.0 million in preferred stock of a privately held corporation with a complementary business line. In October 2019, the Company purchased an additional $4.0 million in preferred stock upon the exercise of an option by the variable interest entity. The Company does not have power over the activities that most significantly impact the economic performance of the variable interest entity and is, therefore, not the primary beneficiary. The Company has the option to purchase all of the outstanding common shares issued by the variable interest entity on the fifth anniversary of the initial preferred stock purchase. Additionally, the Company has extended a $2.5 million revolving line of credit to the variable interest entity to fund its inventory purchases. The Company's investment and amounts loaned under the line of credit are recorded in other long-term assets on its consolidated balance sheet. The outstanding loan balance under the line of credit was $2.5 million as of March 31, 2020 and December 31, 2019. The Company has also entered into a series of agreements to provide ancillary services to the variable interest entity at cost. The Company provided $0.4 million and $0.3 million of these services for the three months ended March 31, 2020 and 2019, respectively, which were recorded against its operating expenses. Investment in Joint Venture In September 2018, the Company acquired a non-controlling equity interest in a joint venture, whereby it has committed to licensing certain intellectual property and contributing up to $2.2 million AUD upon the achievement of specific operational milestones over a period of at least four years from the agreement execution date. As of March 31, 2020, the Company has contributed $0.5 million AUD. This equity investment is accounted for using the equity method and is classified in other long-term assets on the Company's consolidated balance sheet. The Company's share of income and losses from this equity method investment is included in gain (loss) from investment in joint venture on its consolidated statement of operations. Also included in this line item are income and expenses associated with administrative services provided to the joint venture.

Fair Value

3 Months Ended

Mar. 31, 2020

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

Fair Value

Investments

The following table summarizes, by major security type, the Company's assets that are measured at fair value on a recurring basis, and placement within the fair value hierarchy (in thousands):



	As of March 31, 2020
	Fair Value		Level 1		Level 2		Level 3
Assets
Restricted cash	$	1,400	$	1,400	$	—	$	—
Money market funds	1,053		1,053		—		—
Fixed maturities:
Foreign deposits	3,099		3,099		—		—
Municipal bond	995		—		995		—
Investment in variable interest entity	7,625		—		—		7,625
Total	$	14,172	$	5,552	$	995	$	7,625

	As of December 31, 2019
	Fair Value		Level 1		Level 2		Level 3
Assets
Restricted cash	$	1,400	$	1,400	$	—	$	—
Money market funds	1,050		1,050		—		—
Fixed maturities:
Foreign deposits	3,323		3,323		—		—
Municipal bond	1,000		—		1,000		—
Investment in variable interest entity	7,625		—		—		7,625
Total	$	14,398	$	5,773	$	1,000	$	7,625

The Company measures the fair value of restricted cash, money market funds, and foreign deposits based on quoted prices in active markets for identical assets. The fair value of the municipal bond is based on either recent trades in inactive markets or quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. Short-term investments are carried at amortized cost and the fair value is disclosed in Note 3, Investments. The fair value of these investments is determined in the same manner as for available-for-sale securities and is considered a Level 1 measurement.

The Company's preferred stock investment in the variable interest entity (see Note 4) is accounted for as an available-for-sale debt security and measured at fair value at each balance sheet date. The estimated fair value of the preferred stock investment is a Level 3 measurement and is based on certain unobservable inputs such as the value of the underlying enterprise, volatility, time to liquidity, and market interest rates. An increase or decrease in any of these unobservable inputs would result in a change in the fair value measurement. Estimated fair value was $7.6 million as of March 31, 2020, unchanged from December 31, 2019, recorded in other long-term assets on the Company's consolidated balance sheet. An unrealized gain of $0.6 million was recorded in other comprehensive income in the quarter ended December 31, 2019.

Fair Value Disclosures

The Company's other long-term assets balance included notes receivable of $6.0 million as of March 31, 2020 and $6.1 million as of December 31, 2019, recorded at their estimated collectible amount. The Company estimates that the carrying value of the notes receivable approximates the fair value. The estimated fair value represents a Level 3 measurement within the fair value hierarchy and is based on market interest rates and the assessed creditworthiness of the third party. There was no significant activity in Level 3 of the hierarchy during the three months ended March 31, 2020.

The Company estimates the fair value of long-term debt based upon rates currently available to the Company for debt with similar terms and remaining maturities. This is a Level 3 measurement. Based upon the terms of the debt, the carrying amount of long-term debt approximated fair value at March 31, 2020 and December 31, 2019.

The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. There were no transfers between levels for the three months ended March 31, 2020 and the year ended December 31, 2019.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Debt	3 Months Ended
Debt	Mar. 31, 2020
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Debt The Company has a revolving line of credit of up to $50.0 million, maturing June 2022. The facility is secured by any and all interests in the Company's assets that are not otherwise restricted. Interest on the revolving line of credit is payable monthly at the greater of 4.5%, or 0.75% plus the prime rate (4.50% at March 31, 2020). The credit agreement includes other ancillary services and letters of credit of up to $4.5 million. It also requires a deposit of restricted cash of $1.4 million and a minimum cash or investment balance of $2.1 million. The credit agreement requires the Company to comply with various financial and non-financial covenants. As of March 31, 2020, the Company was in compliance with all financial and non-financial covenants required by the credit agreement. Borrowings on the revolving line of credit are limited to the lesser of $50.0 million or the total amount of cash and securities held by the Company's insurance subsidiaries (American Pet Insurance Company and Wyndham Insurance Company (SAC) Limited Segregated Account AX). As of March 31, 2020, available borrowing capacity on the line of credit was $19.2 million, with an outstanding balance of $0.9 million for ancillary services and letters of credit, and borrowings under the facility of $30.0 million, recorded net of financing fees of $0.1 million.

Commitment and Contingencies	3 Months Ended
Commitment and Contingencies	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Commitments and Contingencies Certain state insurance regulators in the United States have contacted the Company regarding whether employees who had helped prospective members enroll by telephone in prior years were required to have an insurance license to conduct such telephone conversations. To date, the Company has resolved each of these matters in non-material amounts and believes it is compliant with the applicable regulations. The Company is currently engaged with a limited number of state insurance regulators to resolve this same legacy issue and believes it has adequately reserved for these matters. In addition, from time to time the Company is or may become subject to various legal proceedings arising in the ordinary course of business, including proceedings against members, other entities or regulatory bodies. Estimated liabilities are recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. At this time, the Company does not believe any such matters to be material individually or in the aggregate. These views are subject to change following the outcome of future events or the results of future developments.

Claims Reserve

3 Months Ended

Mar. 31, 2020

Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]

SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Disclosure [Text Block]

Reserve for Veterinary Invoices

The reserve for veterinary invoices is an estimate of the future amount the Company will pay for veterinary invoices that are dated as of, or prior to, its balance sheet date. The reserve also includes the Company's estimate of related internal processing costs. The reserve estimate involves actuarial projections, and is based on management's assessment of facts and circumstances currently known, and assumptions about anticipated patterns. The Company uses generally accepted actuarial methodologies, such as paid loss development methods, in estimating the amount of the reserve for veterinary invoices. The reserve is made for each of the Company's segments, subscription and other business, and is continually refined as the Company receives and pays veterinary invoices. Changes in management's assumptions and estimates may have a relatively large impact to the reserve and associated expense.

Reserve for veterinary invoices

Summarized below are the changes in the total liability for the Company's subscription business segment (in thousands):



	Three Months Ended March 31,
Subscription	2020		2019
Reserve at beginning of year	$	15,541	$	13,875
Veterinary invoices during the period related to:
Current year	64,816		53,436
Prior years	372		202
Total veterinary invoice expense	65,188		53,638
Amounts paid during the period related to:
Current year	54,000		42,650
Prior years	10,765		10,015
Total paid	64,765		52,665
Non-cash expenses	226		201
Reserve at end of period	$	15,738	$	14,647

The Company's reserve for the subscription business segment increased from $15.5 million at December 31, 2019 to $15.7 million at March 31, 2020. This change was comprised of $65.2 million in expense recorded during the period less $64.8 million in payments of veterinary invoices. The $65.2 million in veterinary invoice expense incurred included an adjustment of $0.4 million to the reserves relating to prior years, which was the result of ongoing analysis of recent payment trends. For the three months ended March 31, 2019, the Company increased prior year reserves by $0.2 million as a result of analysis of payment trends.

Summarized below are the changes in total liability for the Company's other business segment (in thousands):



	Three Months Ended March 31,
Other Business	2020		2019
Reserve at beginning of year	$	5,653	$	2,187
Veterinary invoices during the period related to:
Current year	14,323		7,995
Prior years	129		(351		)
Total veterinary invoice expense	14,452		7,644
Amounts paid during the period related to:
Current year	8,180		5,856
Prior years	4,801		1,447
Total paid	12,981		7,303
Non-cash expenses	—		—
Reserve at end of period	$	7,124	$	2,528

The Company’s reserve for the other business segment increased from $5.7 million at December 31, 2019 to $7.1 million at March 31, 2020. This change was comprised of $14.5 million in expense recorded during the period less $13.0 million in payments of veterinary invoices. The $14.5 million in veterinary invoice expense incurred included an adjustment of $0.1 million to the reserves relating to prior years, which was the result of ongoing analysis of recent payment trends. For the three months ended March 31, 2019, the Company decreased prior year reserves by $0.4 million as a result of analysis of payment trends.

Reserve for veterinary invoices, by year of occurrence

In the following tables, the reserve for veterinary invoices for each segment is presented as the amount (in thousands) by the year to which the veterinary invoice relates, referred to as the year of occurrence.



Subscription	As of March 31, 2020
Year of Occurrence
2018 and prior	$	1,229
2019	3,919
2020	10,590
	$	15,738



Other Business	As of March 31, 2020
Year of Occurrence
2018 and prior	$	46
2019	935
2020	6,143
	$	7,124

Stock-based Compensation

3 Months Ended

Mar. 31, 2020

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

Stock-Based Compensation

Stock-based compensation expense includes stock options, restricted stock awards, and restricted stock units granted to employees and other service providers and has been reported in the Company’s consolidated statements of operations depending on the function performed by the employee or other service provider. Stock-based compensation expense recognized in the consolidated statements of operations was as follows (in thousands):



	Three Months Ended March 31,
	2020		2019
Veterinary invoice expense	$	178	$	161
Other cost of revenue	90		86
Technology and development	100		63
General and administrative	729		618
Sales and marketing	556		429
Total stock-based compensation expense	1,653		1,357
Capitalized stock-based compensation	53		60
Total stock-based compensation	$	1,706	$	1,417

As of March 31, 2020, the Company had 154,839 unvested stock options and 506,863 unvested restricted stock awards and restricted stock units that are expected to vest. Stock-based compensation expenses of $1.1 million related to unvested stock options and $14.1 million related to unvested restricted stock awards and restricted stock units are expected to be recognized over a weighted average period of approximately 1.0 years and 2.8 years, respectively.

Stock Options

A summary of the Company's stock option activity is as follows:



	Number of Options		Weighted Average Exercise Price per Share		Aggregate Intrinsic Value (in thousands)
Outstanding as of December 31, 2019	2,097,978		$	9.86	$	57,907
Granted	—		—		—
Exercised	(48,981	)	10.75		1,035
Forfeited	(2,602	)	16.19		—
Outstanding as of March 31, 2020	2,046,395		9.83		33,155

Exercisable as of March 31, 2020	1,891,556		$	9.19	$	31,848

As of March 31, 2020, stock options outstanding and stock options exercisable had a weighted average remaining contractual life of 4.8 years and 4.6 years, respectively.

Restricted Stock Awards and Restricted Stock Units

A summary of the Company’s restricted stock award and restricted stock unit activity is as follows:



	Number of Shares		Weighted Average Grant Date Fair Value per Share
Unvested shares as of December 31, 2019	581,943		$	29.56
Granted	41,151		31.67
Vested	(102,070	)	29.34
Forfeited	(14,161	)	29.83
Unvested shares as of March 31, 2020	506,863		$	29.76

Leases (Notes)

3 Months Ended

Mar. 31, 2020

Leases [Abstract]

Leases of Lessor Disclosure [Text Block]

Leases

The Company leases certain office space and equipment from third parties and recognizes lease expense on a straight-line basis over the lease term. Leases with an initial term of 12 months or less are not recorded on its consolidated balance sheets.

The Company also leases a portion of its building to third parties and records related rental income within general and administrative expense in the consolidated statements of operations. These leases have remaining initial lease terms of 2 years to 8 years, some of which give the tenants options to renew the leases for up to an additional 10 years, and options to terminate the leases after 3 years of the initial lease terms, with early termination fees required. The Company recorded rental income of $0.6 million for the three months ended March 31, 2020.

The following table summarizes the Company's future rental payments to be received from non-cancellable leases in place as of March 31, 2020 (in thousands):



Year ending December 31:
2020	$	1,460
2021	1,632
2022	1,325
2023	1,367
2024	1,410
Thereafter	1,801
Total rental payments	$	8,995

Stockholders' Equity (Notes)	3 Months Ended
Stockholders' Equity (Notes)	Mar. 31, 2020
Stockholders' Equity Attributable to Parent [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Stockholders' Equity Common Stock and Preferred Stock As of March 31, 2020, the Company had 100,000,000 shares of common stock authorized and 35,084,505 shares of common stock outstanding. Holders of common stock are entitled to one vote on each matter properly submitted to the stockholders of the Company except those related to matters concerning possible outstanding preferred stock. At March 31, 2020, the Company had 10,000,000 shares of undesignated preferred stock authorized for future issuance and did not have any outstanding shares of preferred stock. The holders of common stock are also entitled to receive dividends as and when declared by the board of directors of the Company, whenever funds are legally available. These rights are subordinate to the dividend rights of holders of any senior classes of stock outstanding at the time. The Company is unable to pay dividends to stockholders as of March 31, 2020 due to restrictions in its credit agreements. Share Repurchase Program In November 2019, the Company's board of directors approved a share repurchase program, pursuant to which the Company may repurchase up to $15.0 million of its outstanding shares over the twelve-month period following the approval. The Company repurchased 3,300 shares during the three months ended March 31, 2020. The Company did not repurchase any shares during the year ended December 31, 2019.

Segments

3 Months Ended

Mar. 31, 2020

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

Segments

The Company has two segments: subscription business and other business. The subscription business segment includes revenue and expenses related to monthly pet insurance subscriptions marketed directly to consumers, while the other business segment includes all other business that is not directly marketed to consumers.

The chief operating decision maker reviews revenue, gross profit, and operating income (loss) to evaluate segment performance. Revenue, veterinary invoice expense, other cost of revenue, and sales and marketing expenses are generally directly attributed to each segment. Other operating expenses, such as technology and development expense and general and administrative expense, are allocated proportionately based on revenue in each segment. Interest and other expenses and income taxes are not allocated to the segments, nor included in the measure of segment profit or loss. The Company does not analyze discrete segment balance sheet information related to long-term assets.

Operating income (loss) of the Company’s segments were as follows (in thousands):



	Three Months Ended March 31,
	2020			2019
Subscription business:
Revenue	$	89,484		$	74,222
Veterinary invoice expense	65,188			53,638
Other cost of revenue	8,234			6,749
Gross profit	16,062			13,835
Technology and development	2,287			2,278
General and administrative	4,435			4,624
Sales and marketing	10,279			8,097
Subscription business operating income (loss)	(939		)	(1,164		)

Other business:
Revenue	21,817			12,756
Veterinary invoice expense	14,452			7,644
Other cost of revenue	5,575			3,915
Gross profit	1,790			1,197
Technology and development	558			391
General and administrative	1,081			795
Sales and marketing	163			130
Other business operating income (loss)	(12		)	(119		)
Gain (loss) from investment in joint venture	(59		)	—
Total operating income (loss)	$	(1,010	)	$	(1,283	)

The following table presents the Company’s revenue by geographic region of the member (in thousands):



	Three Months Ended March 31,
	2020		2019
United States	$	92,524	$	71,157
Canada	18,777		15,821
Total revenue	$	111,301	$	86,978

Substantially all of the Company’s long-lived assets were located in the United States as of March 31, 2020 and December 31, 2019.

Related Parties (Notes)	3 Months Ended
Related Parties (Notes)	Mar. 31, 2020
Related Parties [Abstract]
Related Party Transactions Disclosure [Text Block]	Related Parties In August 2018, the Company invested $0.3 million in a limited liability entity in exchange of a 17.5% ownership interest. The investee is considered to be a related party, as the Company has the ability to exercise significant influence over the investee. In February 2020, the Company entered into a service agreement with the investee, under which the Company incurred $0.5 million of expenses for consulting services provided by the investee during the three months ended March 31, 2020.

Nature of Operations and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Description and Basis of Presentation [Text Block]	Description of Business and Basis of Presentation Trupanion, Inc. (collectively with its wholly-owned subsidiaries, the Company) provides medical insurance for cats and dogs throughout the United States, Canada and Puerto Rico. The financial data as of December 31, 2019 was derived from the Company's audited consolidated financial statements. The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and, in management's opinion, have been prepared on the same basis as the audited financial statements and include all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company's financial position, results of operations, comprehensive income (loss), stockholders' equity and cash flows for the interim periods. These unaudited interim consolidated financial statements should be read in conjunction with the Company’s audited financial statements included in the Company’s Annual Report on Form 10-K, filed with the U.S. Securities and Exchange Commission (SEC) on February 13, 2020 (the 2019 10-K). The Company's accounting policies are described in Note 1 to the audited financial statements included in the 2019 10-K. Operating results for the three months ended March 31, 2020 are not necessarily indicative of the results that may be expected for the full fiscal year or any other interim period. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates. See Note 1 to the audited financial statements included in the 2019 10-K for additional discussion of these estimates and assumptions.
Basis of Accounting, Policy [Policy Text Block]	The financial data as of December 31, 2019 was derived from the Company's audited consolidated financial statements. The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and, in management's opinion, have been prepared on the same basis as the audited financial statements and include all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company's financial position, results of operations, comprehensive income (loss), stockholders' equity and cash flows for the interim periods. These unaudited interim consolidated financial statements should be read in conjunction with the Company’s audited financial statements included in the Company’s Annual Report on Form 10-K, filed with the U.S. Securities and Exchange Commission (SEC) on February 13, 2020 (the 2019 10-K). The Company's accounting policies are described in Note 1 to the audited financial statements included in the 2019 10-K. Operating results for the three months ended March 31, 2020 are not necessarily indicative of the results that may be expected for the full fiscal year or any other interim period.
Use of Estimates [Policy Text Block]	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates. See Note 1 to the audited financial statements included in the 2019 10-K for additional discussion of these estimates and assumptions.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements The Company adopted Accounting Standards Update (ASU) 2016-13, Financial Instruments—Credit Losses (Topic 326), using the modified retrospective approach on January 1, 2020. The ASU replaces the incurred loss impairment methodology with a methodology that reflects expected credit losses and requires the use of a forward-looking expected credit loss model for accounts receivables, loans, and other financial instruments. The new standard did not have a material impact on the Company's consolidated statements of operations, balance sheets, stockholders' equity, or cash flows. The Company did not record any cumulative-effect adjustment to its retained earnings upon the adoption.

Other Investments Investment in Variable Interest Entity (Policies)	3 Months Ended
	Mar. 31, 2020
Investments, All Other Investments [Abstract]
Variable Interest Entity Disclosure [Text Block]	Investment in Variable Interest Entity In July 2018, the Company purchased $3.0 million in preferred stock of a privately held corporation with a complementary business line. In October 2019, the Company purchased an additional $4.0 million in preferred stock upon the exercise of an option by the variable interest entity. The Company does not have power over the activities that most significantly impact the economic performance of the variable interest entity and is, therefore, not the primary beneficiary. The Company has the option to purchase all of the outstanding common shares issued by the variable interest entity on the fifth anniversary of the initial preferred stock purchase. Additionally, the Company has extended a $2.5 million revolving line of credit to the variable interest entity to fund its inventory purchases. The Company's investment and amounts loaned under the line of credit are recorded in other long-term assets on its consolidated balance sheet. The outstanding loan balance under the line of credit was $2.5 million as of March 31, 2020 and December 31, 2019.

Other Investments Investment in Joint Venture (Policies)	3 Months Ended
	Mar. 31, 2020
Investments, All Other Investments [Abstract]
Equity Method Investments and Joint Ventures Disclosure [Text Block]	Investment in Joint Venture In September 2018, the Company acquired a non-controlling equity interest in a joint venture, whereby it has committed to licensing certain intellectual property and contributing up to $2.2 million AUD upon the achievement of specific operational milestones over a period of at least four years from the agreement execution date. As of March 31, 2020, the Company has contributed $0.5 million AUD. This equity investment is accounted for using the equity method and is classified in other long-term assets on the Company's consolidated balance sheet. The Company's share of income and losses from this equity method investment is included in gain (loss) from investment in joint venture on its consolidated statement of operations. Also included in this line item are income and expenses associated with administrative services provided to the joint venture.

Fair Value Notes Receivable (Policies)	3 Months Ended
Fair Value Notes Receivable (Policies)	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	The Company's other long-term assets balance included notes receivable of $6.0 million as of March 31, 2020 and $6.1 million as of December 31, 2019, recorded at their estimated collectible amount. The Company estimates that the carrying value of the notes receivable approximates the fair value. The estimated fair value represents a Level 3 measurement within the fair value hierarchy and is based on market interest rates and the assessed creditworthiness of the third party. There was no significant activity in Level 3 of the hierarchy during the three months ended March 31, 2020. The Company estimates the fair value of long-term debt based upon rates currently available to the Company for debt with similar terms and remaining maturities. This is a Level 3 measurement. Based upon the terms of the debt, the carrying amount of long-term debt approximated fair value at March 31, 2020 and December 31, 2019. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. There were no transfers between levels for the three months ended March 31, 2020 and the year ended December 31, 2019.

- Definition

The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.

+ References + Details

Claims Reserve Claims Reserve (Policies)	3 Months Ended
Claims Reserve Claims Reserve (Policies)	Mar. 31, 2020
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]
Liability Reserve Estimate, Policy [Policy Text Block]	Reserve for Veterinary Invoices The reserve for veterinary invoices is an estimate of the future amount the Company will pay for veterinary invoices that are dated as of, or prior to, its balance sheet date. The reserve also includes the Company's estimate of related internal processing costs. The reserve estimate involves actuarial projections, and is based on management's assessment of facts and circumstances currently known, and assumptions about anticipated patterns. The Company uses generally accepted actuarial methodologies, such as paid loss development methods, in estimating the amount of the reserve for veterinary invoices. The reserve is made for each of the Company's segments, subscription and other business, and is continually refined as the Company receives and pays veterinary invoices. Changes in management's assumptions and estimates may have a relatively large impact to the reserve and associated expense.

Segments Segments (Policies)	3 Months Ended
Segments Segments (Policies)	Mar. 31, 2020
Segment Reporting [Abstract]
Segment Reporting, Policy [Policy Text Block]	The Company has two segments: subscription business and other business. The subscription business segment includes revenue and expenses related to monthly pet insurance subscriptions marketed directly to consumers, while the other business segment includes all other business that is not directly marketed to consumers. The chief operating decision maker reviews revenue, gross profit, and operating income (loss) to evaluate segment performance. Revenue, veterinary invoice expense, other cost of revenue, and sales and marketing expenses are generally directly attributed to each segment. Other operating expenses, such as technology and development expense and general and administrative expense, are allocated proportionately based on revenue in each segment. Interest and other expenses and income taxes are not allocated to the segments, nor included in the measure of segment profit or loss. The Company does not analyze discrete segment balance sheet information related to long-term assets.

Net Loss per Share (Tables)

3 Months Ended

Mar. 31, 2020

Schedule of Earnings Per Share, Basic and Diluted [Line Items]

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

The following potentially dilutive equity securities were not included in the diluted earnings per share of common stock calculation because they would have had an antidilutive effect:



	Three Months Ended March 31,
	2020	2019
Stock options	2,046,395	2,513,946
Restricted stock awards and restricted stock units	506,863	716,319
Warrants	—	30,000

Investment Securities Available-for-Sale (Tables)

3 Months Ended

Mar. 31, 2020

Investments [Abstract]

Unrealized Gain (Loss) on Investments [Table Text Block]

The amortized cost, gross unrealized holding gains and losses, and estimates of fair value of long-term and short-term investments by major security type and class of security were as follows as of March 31, 2020 and December 31, 2019 (in thousands):



	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Fair Value
As of March 31, 2020
Long-term investments:
Foreign deposits	$	3,099	$	—	$	—		$	3,099
Municipal bond	1,000		—		(5		)	995
	$	4,099	$	—	$	(5	)	$	4,094
Short-term investments:
U.S. Treasury securities	$	6,159	$	11	$	—		$	6,170
Certificates of deposit	1,565		—		—			1,565
U.S. government funds	68,370		—		—			68,370
	$	76,094	$	11	$	—		$	76,105

	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Fair Value
As of December 31, 2019
Long-term investments:
Foreign deposits	$	3,323	$	—	$	—		$	3,323
Municipal bond	1,000		—		—			1,000
	$	4,323	$	—	$	—		$	4,323
Short-term investments:
U.S. Treasury securities	$	6,156	$	—	$	(1	)	$	6,155
Certificates of deposit	440		—		—			440
U.S. government funds	63,136		—		—			63,136
	$	69,732	$	—	$	(1	)	$	69,731

Available-for-sale Securities [Table Text Block]

Maturities of debt securities classified as available-for-sale were as follows (in thousands):



	As of March 31, 2020
	Amortized Cost		Fair Value
Available-for-sale:
Due after one year through five years	$	4,099	$	4,094
	$	4,099	$	4,094

Fair Value (Tables)

3 Months Ended

Mar. 31, 2020

Fair Value Disclosures [Abstract]

Fair value, asset & liabilities measured on recurring basis [Table Text Block]

The following table summarizes, by major security type, the Company's assets that are measured at fair value on a recurring basis, and placement within the fair value hierarchy (in thousands):



	As of March 31, 2020
	Fair Value		Level 1		Level 2		Level 3
Assets
Restricted cash	$	1,400	$	1,400	$	—	$	—
Money market funds	1,053		1,053		—		—
Fixed maturities:
Foreign deposits	3,099		3,099		—		—
Municipal bond	995		—		995		—
Investment in variable interest entity	7,625		—		—		7,625
Total	$	14,172	$	5,552	$	995	$	7,625

	As of December 31, 2019
	Fair Value		Level 1		Level 2		Level 3
Assets
Restricted cash	$	1,400	$	1,400	$	—	$	—
Money market funds	1,050		1,050		—		—
Fixed maturities:
Foreign deposits	3,323		3,323		—		—
Municipal bond	1,000		—		1,000		—
Investment in variable interest entity	7,625		—		—		7,625
Total	$	14,398	$	5,773	$	1,000	$	7,625

Claims Reserve (Tables)

3 Months Ended

Mar. 31, 2020

Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]

Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]

Summarized below are the changes in the total liability for the Company's subscription business segment (in thousands):



	Three Months Ended March 31,
Subscription	2020		2019
Reserve at beginning of year	$	15,541	$	13,875
Veterinary invoices during the period related to:
Current year	64,816		53,436
Prior years	372		202
Total veterinary invoice expense	65,188		53,638
Amounts paid during the period related to:
Current year	54,000		42,650
Prior years	10,765		10,015
Total paid	64,765		52,665
Non-cash expenses	226		201
Reserve at end of period	$	15,738	$	14,647

The Company's reserve for the subscription business segment increased from $15.5 million at December 31, 2019 to $15.7 million at March 31, 2020. This change was comprised of $65.2 million in expense recorded during the period less $64.8 million in payments of veterinary invoices. The $65.2 million in veterinary invoice expense incurred included an adjustment of $0.4 million to the reserves relating to prior years, which was the result of ongoing analysis of recent payment trends. For the three months ended March 31, 2019, the Company increased prior year reserves by $0.2 million as a result of analysis of payment trends.

Summarized below are the changes in total liability for the Company's other business segment (in thousands):



	Three Months Ended March 31,
Other Business	2020		2019
Reserve at beginning of year	$	5,653	$	2,187
Veterinary invoices during the period related to:
Current year	14,323		7,995
Prior years	129		(351		)
Total veterinary invoice expense	14,452		7,644
Amounts paid during the period related to:
Current year	8,180		5,856
Prior years	4,801		1,447
Total paid	12,981		7,303
Non-cash expenses	—		—
Reserve at end of period	$	7,124	$	2,528

The Company’s reserve for the other business segment increased from $5.7 million at December 31, 2019 to $7.1 million at March 31, 2020. This change was comprised of $14.5 million in expense recorded during the period less $13.0 million in payments of veterinary invoices. The $14.5 million in veterinary invoice expense incurred included an adjustment of $0.1 million to the reserves relating to prior years, which was the result of ongoing analysis of recent payment trends. For the three months ended March 31, 2019, the Company decreased prior year reserves by $0.4 million as a result of analysis of payment trends.

IBRN plus expected development on reported claims[Table Text Block]

In the following tables, the reserve for veterinary invoices for each segment is presented as the amount (in thousands) by the year to which the veterinary invoice relates, referred to as the year of occurrence.



Subscription	As of March 31, 2020
Year of Occurrence
2018 and prior	$	1,229
2019	3,919
2020	10,590
	$	15,738



Other Business	As of March 31, 2020
Year of Occurrence
2018 and prior	$	46
2019	935
2020	6,143
	$	7,124

Stock-based Compensation (Tables)

3 Months Ended

Mar. 31, 2020

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

Stock-based compensation expense includes stock options, restricted stock awards, and restricted stock units granted to employees and other service providers and has been reported in the Company’s consolidated statements of operations depending on the function performed by the employee or other service provider. Stock-based compensation expense recognized in the consolidated statements of operations was as follows (in thousands):



	Three Months Ended March 31,
	2020		2019
Veterinary invoice expense	$	178	$	161
Other cost of revenue	90		86
Technology and development	100		63
General and administrative	729		618
Sales and marketing	556		429
Total stock-based compensation expense	1,653		1,357
Capitalized stock-based compensation	53		60
Total stock-based compensation	$	1,706	$	1,417

As of March 31, 2020, the Company had 154,839 unvested stock options and 506,863 unvested restricted stock awards and restricted stock units that are expected to vest. Stock-based compensation expenses of $1.1 million related to unvested stock options and $14.1 million related to unvested restricted stock awards and restricted stock units are expected to be recognized over a weighted average period of approximately 1.0 years and 2.8 years, respectively.

Share-based Compensation, Stock Options, Activity [Table Text Block]

A summary of the Company's stock option activity is as follows:



	Number of Options		Weighted Average Exercise Price per Share		Aggregate Intrinsic Value (in thousands)
Outstanding as of December 31, 2019	2,097,978		$	9.86	$	57,907
Granted	—		—		—
Exercised	(48,981	)	10.75		1,035
Forfeited	(2,602	)	16.19		—
Outstanding as of March 31, 2020	2,046,395		9.83		33,155

Exercisable as of March 31, 2020	1,891,556		$	9.19	$	31,848

As of March 31, 2020, stock options outstanding and stock options exercisable had a weighted average remaining contractual life of 4.8 years and 4.6 years, respectively.

Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]

A summary of the Company’s restricted stock award and restricted stock unit activity is as follows:



	Number of Shares		Weighted Average Grant Date Fair Value per Share
Unvested shares as of December 31, 2019	581,943		$	29.56
Granted	41,151		31.67
Vested	(102,070	)	29.34
Forfeited	(14,161	)	29.83
Unvested shares as of March 31, 2020	506,863		$	29.76

Segments (Tables)

3 Months Ended

Mar. 31, 2020

Segment Reporting [Abstract]

Revenue and Gross Profit from Segments [Table Text Block]

Operating income (loss) of the Company’s segments were as follows (in thousands):



	Three Months Ended March 31,
	2020			2019
Subscription business:
Revenue	$	89,484		$	74,222
Veterinary invoice expense	65,188			53,638
Other cost of revenue	8,234			6,749
Gross profit	16,062			13,835
Technology and development	2,287			2,278
General and administrative	4,435			4,624
Sales and marketing	10,279			8,097
Subscription business operating income (loss)	(939		)	(1,164		)

Other business:
Revenue	21,817			12,756
Veterinary invoice expense	14,452			7,644
Other cost of revenue	5,575			3,915
Gross profit	1,790			1,197
Technology and development	558			391
General and administrative	1,081			795
Sales and marketing	163			130
Other business operating income (loss)	(12		)	(119		)
Gain (loss) from investment in joint venture	(59		)	—
Total operating income (loss)	$	(1,010	)	$	(1,283	)

Revenue from External Customers by Geographic Areas [Table Text Block]

The following table presents the Company’s revenue by geographic region of the member (in thousands):



	Three Months Ended March 31,
	2020		2019
United States	$	92,524	$	71,157
Canada	18,777		15,821
Total revenue	$	111,301	$	86,978

Net Loss per Share (Details) Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share - shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,046,395	2,513,946
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	506,863	716,319
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	30,000

Net Loss per Share Computation of Net Income (Loss) Per Share (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Schedule of Earnings Per Share, Basic and Diluted [Line Items]
Net Income (Loss) Available to Common Stockholders, Basic	$ (1,133)	$ (1,296)
Net Loss	$ (1,133)	$ (1,296)

Investment Securities (Details) Investment Schedule - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Schedule of Investments [Line Items]
Debt Securities, Held-to-maturity	$ 76,094	$ 69,732
Debt Securities, Available-for-sale	4,099	4,323
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	0	0
Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain	11	0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	5	0
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	4,094	4,323
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss	0	1
Debt Securities, Held-to-maturity, Fair Value	76,105	69,731
Deposits [Member]
Schedule of Investments [Line Items]
Debt Securities, Available-for-sale	3,099	3,323
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	0	0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	0	0
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	3,099	3,323
Municipal Bonds [Member]
Schedule of Investments [Line Items]
Debt Securities, Available-for-sale	1,000	1,000
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	0	0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	5	0
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	995	1,000
US Treasury Securities [Member]
Schedule of Investments [Line Items]
Debt Securities, Held-to-maturity	6,159	6,156
Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain	11	0
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss	0	1
Debt Securities, Held-to-maturity, Fair Value	6,170	6,155
Certificates of Deposit [Member]
Schedule of Investments [Line Items]
Debt Securities, Held-to-maturity	1,565	440
Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain	0	0
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss	0	0
Debt Securities, Held-to-maturity, Fair Value	1,565	440
US Government Debt Securities [Member]
Schedule of Investments [Line Items]
Debt Securities, Held-to-maturity	68,370	63,136
Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain	0	0
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss	0	0
Debt Securities, Held-to-maturity, Fair Value	$ 68,370	$ 63,136

Investment Securities (Details) Available-for-Sale - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Debt Securities, Available-for-sale [Abstract]
Available-for-sale securities, debt maturities, year two through five, amortized cost basis	$ 4,099
Available-for-sale securities, debt maturities, year two through five, fair value	4,094
Available-for-sale securities, amortized cost	4,099
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	$ 4,094	$ 4,323

Other Investments (Details) - USD ($) $ in Millions	3 Months Ended
Other Investments (Details) - USD ($) $ in Millions	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018
Investments, All Other Investments [Abstract]
Purchase of Equity Interest			$ 4.0	$ 3.0
Other Commitment	$ 2.2
Increase (Decrease) in Notes Receivables	2.5
Loans Receivable, Net	2.5		$ 2.5
Payments to Acquire Interest in Joint Venture	0.5
Services performed for Variable Interest Entity	$ 0.4	$ 0.3

Fair Value (Details) Unobservable - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Cash	$ 1,400,000	$ 1,400,000
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	4,094,000	4,323,000
Noncontrolling Interest in Variable Interest Entity	7,625,000	7,625,000
Assets, Fair Value Disclosure	14,172,000	14,398,000
Notes Receivable, Fair Value Disclosure	6,000,000.0	6,100,000
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncontrolling Interest in Variable Interest Entity	0	0
Assets, Fair Value Disclosure	5,552,000	5,773,000
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncontrolling Interest in Variable Interest Entity	0	0
Assets, Fair Value Disclosure	995,000	1,000,000
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncontrolling Interest in Variable Interest Entity	7,625,000	7,625,000
Assets, Fair Value Disclosure	7,625,000	7,625,000
Cash and Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Cash	1,400,000	1,400,000
Cash and Cash Equivalents [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Cash	1,400,000	1,400,000
Cash and Cash Equivalents [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Cash	0	0
Cash and Cash Equivalents [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Cash	0	0
Deposits [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	3,099,000	3,323,000
Cash and Cash Equivalents, Fair Value Disclosure	1,053,000	1,050,000
Deposits [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	3,099,000	3,323,000
Cash and Cash Equivalents, Fair Value Disclosure	1,053,000	1,050,000
Deposits [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	0	0
Cash and Cash Equivalents, Fair Value Disclosure	0	0
Deposits [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	0	0
Cash and Cash Equivalents, Fair Value Disclosure	0	0
Municipal bond
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	995,000	1,000,000
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value	995,000	1,000,000
Municipal bond \| Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value	0	0
Municipal bond \| Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value	995,000	1,000,000
Municipal bond \| Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value	$ 0	$ 0

Fair Value (Details) Narrative - USD ($) $ in Thousands	3 Months Ended
Fair Value (Details) Narrative - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019	Dec. 31, 2018
Note Receivable, Fair Value [Abstract]
Net unrealized (loss) gain on available-for-sale debt securities	$ (5)		$ 19
Notes Receivable, Fair Value Disclosure	6,000	$ 6,100
Purchase of Equity Interest		4,000		$ 3,000
Noncontrolling Interest in Variable Interest Entity	$ 7,625	7,625
Unrealized Gain (Loss) on Investments		$ 600

Debt (Details) Narrative $ in Millions	3 Months Ended
Debt (Details) Narrative $ in Millions	Mar. 31, 2020 USD ($)
Debt Disclosure [Abstract]
Line of Credit Facility, Maximum Borrowing Capacity	$ 50.0
Line of credit facility, interest rate description	greater of 4.5%, or 0.75% plus the prime rate
Line of Credit Facility, Interest Rate During Period	4.50%
Line of Credit Facility, Ancillary Services and Letter of Credit	$ 4.5
Restricted Cash and Cash Equivalents	1.4
Minimum Cash or Investment Balance Required	2.1
Line of Credit Facility, Remaining Borrowing Capacity	19.2
Line of Credit Facility, Ancillary Services and Letter of Credit	0.9
Long-term Line of Credit	30.0
Line of Credit Financing Fee	$ 0.1

Claims Reserve (Details) Claims Loss Roll-forward - Other business - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]
Claims Reserve	$ 7,124	$ 2,528	$ 5,653	$ 2,187
Current Year Claims Incurred	14,323	7,995
Prior Year Claims Incurred	129	(351)
Total Claims Incurred	14,452	7,644
Current Year Claims Paid	8,180	5,856
Prior Years Claims Paid	4,801	1,447
Total Claims Paid	12,981	7,303
Claims expense non-cash	0	$ 0
Claims Reserve by Loss Year
Incurred but Not Reported (IBNR) Claims Liability	7,124
Short-duration Insurance Contracts, Accident Year 2019 [Member]
Claims Reserve by Loss Year
Incurred but Not Reported (IBNR) Claims Liability	935
Short-duration Insurance Contracts, Accident Year 2020 [Member]
Claims Reserve by Loss Year
Incurred but Not Reported (IBNR) Claims Liability	$ 6,143

Claims Reserve (Details) Narrative - USD ($) $ in Thousands	3 Months Ended
Claims Reserve (Details) Narrative - USD ($) $ in Thousands	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018
Subscription business
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]
Claims Reserve	$ 15,738	$ 14,647	$ 15,541	$ 13,875
Total Claims Incurred	65,188	53,638
Total Claims Paid	64,765	52,665
Prior Year Claims Incurred	372	202
Other business
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]
Claims Reserve	7,124	2,528	$ 5,653	$ 2,187
Total Claims Incurred	14,452	7,644
Total Claims Paid	12,981	7,303
Prior Year Claims Incurred	$ 129	$ (351)

Claims Reserve Claims Reserve (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018
Subscription business
Liability for Claims and Claims Adjustment Expense [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	$ 15,738
Claims Reserve	15,738	$ 14,647	$ 15,541	$ 13,875
Current Year Claims Incurred	64,816	53,436
Prior Year Claims Incurred	372	202
Current Year Claims Paid	54,000	42,650
Prior Years Claims Paid	10,765	10,015
Total Claims Paid	64,765	52,665
Claims expense non-cash	226	201
Total Claims Incurred	65,188	53,638
Other business
Liability for Claims and Claims Adjustment Expense [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	7,124
Claims Reserve	7,124	2,528	$ 5,653	$ 2,187
Current Year Claims Incurred	14,323	7,995
Prior Year Claims Incurred	129	(351)
Current Year Claims Paid	8,180	5,856
Prior Years Claims Paid	4,801	1,447
Total Claims Paid	12,981	7,303
Claims expense non-cash	0	0
Total Claims Incurred	14,452	$ 7,644
Short-duration Insurance Contracts, Accident Year 2018 [Member] \| Subscription business
Liability for Claims and Claims Adjustment Expense [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	1,229
Short-duration Insurance Contracts, Accident Year 2018 [Member] \| Other business
Liability for Claims and Claims Adjustment Expense [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	46
Short-duration Insurance Contracts, Accident Year 2019 [Member] \| Subscription business
Liability for Claims and Claims Adjustment Expense [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	3,919
Short-duration Insurance Contracts, Accident Year 2019 [Member] \| Other business
Liability for Claims and Claims Adjustment Expense [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	935
Short-duration Insurance Contracts, Accident Year 2020 [Member] \| Subscription business
Liability for Claims and Claims Adjustment Expense [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	10,590
Short-duration Insurance Contracts, Accident Year 2020 [Member] \| Other business
Liability for Claims and Claims Adjustment Expense [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	$ 6,143

Stock-based Compensation (Details) Expense Category - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Stock-based Compensation
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	$ 1,706	$ 1,417
Share-based Compensation Arrangement by Share-based Payment Award, Capitalized Cost	53	60
Claims expense
Stock-based Compensation
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	178	161
Other Cost of Revenue
Stock-based Compensation
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	90	86
Technology and development
Stock-based Compensation
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	100	63
General and administrative
Stock-based Compensation
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	729	618
Sales and marketing
Stock-based Compensation
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	556	429
Total Expense [Member]
Stock-based Compensation
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	$ 1,653	$ 1,357
Restricted Stock Units (RSUs) [Member]
Stock-based Compensation
Employee share-based compensation arrangement and non-employee, weighted average remaining vesting period	2 years 9 months 18 days
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 14,100
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	506,863
Employee Stock Option [Member]
Stock-based Compensation
Employee share-based compensation arrangement and non-employee, weighted average remaining vesting period	1 year
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 1,100
Employee share-based compensation arrangement by share-based payment award, options, nonvested, number of shares	154,839

Stock-based Compensation (Details) Options Granted, Exercised and Forfeited - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based compensation, options, outstanding, number of shares	2,046,395	2,097,978
Stock-based compensation, options, granted, number of options	0
Stock-based compensation, options, exercised	(48,981)
Stock-based compensation, options, forfeited	(2,602)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	1,891,556
Stock-based compensation, options, outstanding, weighted-average exercise price	$ 9.83	$ 9.86
Stock-based compensation, options, granted, weighted-average exercise price	0
Stock-based compensation, options, exercised, weighted-average exercise price	10.75
Stock-based compensation, options, forfeited, weighted-average exercise price	16.19
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	$ 9.19
Stock-based compensation, options, outstanding, aggregate intrinsic value	$ 33,155	$ 57,907
Stock-based compensation, options, exercised, aggregate intrinsic value	1,035
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value	$ 31,848
Remaining contractual life, share-based payments, weighted average	4 years 9 months 18 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term	4 years 7 months 6 days

Stock-based Compensation Restricted Stock Awards (Details) - Restricted Stock [Member] - $ / shares	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	506,863	581,943
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	41,151
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	(14,161)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	(102,070)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Grant Date Fair Value [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value	$ 29.76	$ 29.56
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	31.67
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value	29.83
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value	$ 29.34

Leases (Details) $ in Thousands	3 Months Ended
Leases (Details) $ in Thousands	Mar. 31, 2020 USD ($)
Leases [Abstract]
Proceeds from Rents Received	$ 600
Operating Leases, Future Minimum Payments Receivable, Current	1,460
Operating Leases, Future Minimum Payments Receivable, in Two Years	1,632
Operating Leases, Future Minimum Payments Receivable, in Three Years	1,325
Operating Leases, Future Minimum Payments Receivable, in Four Years	1,367
Operating Leases, Future Minimum Payments Receivable, in Five Years	1,410
Operating Leases, Future Minimum Payments Receivable, Thereafter	1,801
Operating Leases, Future Minimum Payments Receivable	$ 8,995

Stockholders' Equity (Details) - USD ($) $ in Millions	3 Months Ended
Stockholders' Equity (Details) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Stockholders' Equity Attributable to Parent [Abstract]
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares, Outstanding	35,084,505	34,947,017
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Stock Repurchase Program, Authorized Amount	$ 15.0
Stock Repurchased During Period, Shares	3,300

Segments (Details) Business Segment - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Segment Reporting Information [Line Items]
Revenue	$ 111,301	$ 86,978
Veterinary invoice expense	79,640	61,282
Other Cost of Services Sold	13,809	10,664
Gross profit	17,852	15,032
Operating Expenses	18,803	16,315
Technology and Development Expense	2,845	2,669
General and administrative	5,516	5,419
Sales and marketing	10,442	8,227
Income (Loss) from Equity Method Investments	(59)	0
Operating loss	(1,010)	(1,283)
Subscription business
Segment Reporting Information [Line Items]
Revenue	89,484	74,222
Veterinary invoice expense	65,188	53,638
Other Cost of Services Sold	8,234	6,749
Gross profit	16,062	13,835
Technology and Development Expense	2,287	2,278
General and administrative	4,435	4,624
Sales and marketing	10,279	8,097
Operating loss	(939)	(1,164)
Other business
Segment Reporting Information [Line Items]
Revenue	21,817	12,756
Veterinary invoice expense	14,452	7,644
Other Cost of Services Sold	5,575	3,915
Gross profit	1,790	1,197
Technology and Development Expense	558	391
General and administrative	1,081	795
Sales and marketing	163	130
Operating loss	$ (12)	$ (119)

Segments (Details) Revenue by Geography - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Segment Reporting Information [Line Items]
Revenues	$ 111,301	$ 86,978
CANADA
Segment Reporting Information [Line Items]
Revenues	18,777	15,821
UNITED STATES
Segment Reporting Information [Line Items]
Revenues	$ 92,524	$ 71,157

Related Parties (Details) $ in Millions	3 Months Ended
Related Parties (Details) $ in Millions	Mar. 31, 2020 USD ($)
Related Parties [Abstract]
Equity Method Investments	$ 0.3
Equity Method Investment, Ownership Percentage	17.50%
Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party	$ 0.5

Label	Element	Value
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	$ 30,568,000
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	$ 27,952,000